What Has Been Achieved To Date?

AGM2026

140

Total patients treated with azer-cel in Phase 1 and Phase 1b clinical trials

77%

response rate (Phase 1b) in 56 patients across B-cell cancers

86%

ORR in early BTKi combination data (6 of 7 patients)

COMBINATION DOSING STRATEGY FOR BTKI FAILURES	BTK inhibitors are a ~US$12bn global market (2025).
PEER RECOGNITION	Oral presentations at ASH 2025 and ASCO 2026,as well as selection for a Poster presentation at ASH in December 2026
SAFETY PROFILE	No GvHD and no grade ≥3 CRS in Phase 1b.
EMERGING REGULATORY PATH	Data from BTKi combinations is encouraging.
FDA ENGAGEMENT	Positive Type C meeting, November 2025.
DRUG INVENTORY SECURED	Clinical doses available to complete Phase 1b and commence the Phase 2 pivotal study.
LEAN AND FOCUSED	Single-asset focus; cost base cut ~40%, with every dollar directed to azer-cel.

ORR overall response rate · **BTKi** Bruton tyrosine kinase inhibitor · **GvHD** graft-versus-host disease · **CRS** cytokine release syndrome · **ASH** American Society of Hematology
ASCO American Society of Clinical Oncology · **FDA** US Food and Drug Administration

What Comes Next?

DEC 2026	ASH 2026 presentation of initial BTKi combination data
Q2 2027	Complete Phase 1b enrolment
MID 2027	FDA Type B meeting to confirm the registrational pathway for BTKi combination therapy
2H 2027/2028	Initiate registrational study
PARTNERING	Out-licensing discussions underway

ASH American Society of Hematology · **BTKi** Bruton tyrosine kinase inhibitor · **FDA** US Food and Drug Administration

Remuneration Matters

AGM2026

- Directors and Leadership have not been granted equity allocations this year
- Additionally, no salary increases CEO or Executive Chair in the past 12 months and no increases to non-Executive Director fees
- Work force has been reduced substantially this calendar year, and high compensation individuals have left the organization, significantly decreasing the remuneration costs by $4.2m
- Senior positions (e.g. CMO) are covered by fractional consultants that significantly curtails spend
- Additionally, any future hires for senior positions will be at a compensation level that is commensurate with the company's market cap, and established pay levels and structure for ASX listed companies in our sector

$4.2m

reduction in remuneration costs